Clifford Chance advises Permira on Neuraxpharm acquisition
Clifford Chance has advised Private Equity firm Permira on the acquisition of leading European pharmaceutical company Neuraxpharm
Permira has acquired the leading European CNS specialty pharmaceutical company Neuraxpharm through a company backed by the Permira funds, from funds advised by Apax Partners.
Neuraxpharm is one of the fastest growing specialty pharmaceutical companies in Europe with annual revenues in excess of €460 million and 850 employees. The company is focused on the treatment of the central nervous system (CNS), developing and commercializing value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders. Neuraxpharm enjoys leading positions in its core markets Germany and Spain.
Permira funds invest in high-growth businesses in resilient end-markets, with longstanding global track-record in successfully transforming market leaders and proven expertise in the healthcare sector. With Neuraxpharm, Permira will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of the company’s product pipeline and backing its buy-and-build strategy to further expand internationally.
A cross-border team from Clifford Chance Düsseldorf, Frankfurt, London, Madrid and Barcelona offices advised Permira on the deal. The Madrid and Barcelona offices team included M&A partners Samir Azzouzi Maanan (Pictured left) form the Madrid office and Guillermo Guardia (pictured right) from the Barcelona office, Administrative Law counsel Carme Briera Dalmau (Barcelona) and associates Sònia Sebé Marín (Barcelona), Daniel García Juárez and Patricia Puertas Díaz (both from Madrid).